



PROGRAM

October 1–2, 2019

Miltenyi Biotec Campus

Bergisch Gladbach, Germany

DCID & Next Generation Vaccines Days

► miltenyibiotec.com



Miltenyi Biotec



Miltenyi Biotec

Miltenyi Biotec B.V. & Co. KG

Friedrich-Ebert-Straße 68 | 51429 Bergisch Gladbach | Germany

Phone +49 2204 8306-0 | Fax +49 2204 85197

macs@miltenyibiotec.de | www.miltenyibiotec.com

Miltenyi Biotec provides products and services worldwide.

Visit www.miltenyibiotec.com/local to find your nearest

Miltenyi Biotec contact.

The statements and other contributions presented at the meeting and the views expressed therein are those of the attending experts and do not necessarily represent the policy or opinion of Miltenyi Biotec or any institution the respective expert may be associated with. Neither Miltenyi Biotec nor any of its directors or employees give any representation or warranty as to the reliability, accuracy, or completeness of the content thereof. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. This notice must accompany any further distribution of this document. Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research use only and not for therapeutic or diagnostic use. MACS and the MACS logo are registered trademarks or trademarks of Miltenyi Biotec B.V & Co. KG and/or its affiliates in various countries worldwide. Copyright © 2019 Miltenyi Biotec B.V & Co. KG and/or its affiliates. All rights reserved.

Tuesday, October 1, 2019

09:30 a.m. Registration

Session 1 Regulation and manufacturing of cancer vaccines

11:00 a.m. Critical aspects in delivery of monocytederived cellular therapies – preparation for large scale trials

John Campbell, Scottish National Blood Transfusion Service, Edinburgh, UK

Empowering dendritic cells, regulatory compliant manufacture process development

Koen Bezemer, Erasmus MC, Rotterdam, Netherlands

Development and regulation of personalized cancer immunotherapy products

Thomas Hinz, Paul-Ehrlich-Institut, Langen, Germany

Panel discussion

01:00 p.m. Lunch

02:00 p.m. Miltenyi Biotec campus tour

Session 2 Advanced biomaterials for vaccine design

03:00 p.m. Development of personalized cancer nanovaccines against neoantigens

Li Tang, École polytechnique fédérale de Lausanne, Switzerland

Nanoparticle-based anticancer vaccine design with tumor-associated glycopeptides

Joseph Barchi, National Cancer Institute, Bethesda, Maryland, USA

04:00 p.m. Break

04:30 p.m. Bioengineering lentivirus-induced dendritic cells for immune therapy of leukemia and HCMV and testing in fully humanized mouse systems

Renata Stripecke, Immunology Centre Hannover, Hannover Medical School, Germany

Serum and liver – how to overcome these obstacles to efficacy of systemically applied nanovaccines

Matthias Bros, University Medical Center of the Johannes Gutenberg University Mainz, Germany

Panel discussion

06:00 p.m. Shuttle to networking dinner

Wednesday, October 2, 2019

Session 3 **Cancer vaccines and combination therapy**

09:00 a.m. **Next generation DC vaccines using interleukin-15 and *in situ* suppression of programmed death signaling**

Eva Lion, Laboratory of Experimental Hematology, University of Antwerp, Belgium

Exploring the therapeutic potential of intratumoral myeloid dendritic cell therapy

Bart Neyns, Oncology Center, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Belgium

Accuracy of dendritic cell vaccines plus chemotherapy in the neoadjuvant scenario in breast cancer patients

Marta Santisteban Eslava, Clínica Universidad de Navarra, Spain

Dendritic cells application in diffuse pontine glioma (DIPG)

Daniel Benítez, Hospital Clínic de Barcelona, Spain

Panel discussion

11:30 a.m. **Break**

Session 4 **Advanced biomaterials for vaccine design**

11:50 p.m. **Nanovaccines remodel tumor immune microenvironment, sensitizing solid tumors to immune checkpoint therapy**
Helena Florindo, University of Lisbon, Portugal

Gaining spatial control over innate immune activation by synthetic macromolecular conjugates of small molecule TLR7/8 agonists
Bruno de Geest, Cancer Research Institute Ghent, Belgium

Panel discussion

01:15 p.m. **Lunch**

Session 5 **Cancer vaccines and combination therapy**

02:00 p.m. **Blood-derived dendritic cell vaccinations in castration-resistant prostate cancer**
Harm Westdorp, Radboud University Nijmegen, the Netherlands

Targeting MAPK pathways in natural DC subsets for next generation DC vaccine
Andrew Jackson, Nottingham City Hospital, UK

The challenges of delivering ATMPs in an academic centre
Stuart Curbishley, Centre for Liver Research, University of Birmingham, UK

Panel discussion

04:10 p.m. **Closing remarks**